SCHEMBL10036396

SCHEMBL10036396

Cc1cc(N)ccc1N1CCC(C(F)(F)F)CC1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.59
ALDH1A1 P00352 7/20 0.59
GAA P10253 6/20 0.59
MEN1 O00255 4/20 0.59
KMT2A Q03164 4/20 0.59
THRB P10828 3/20 0.59
NR4A1 P22736 2/20 0.59
PTK2B Q14289 1/20 0.59
GFER P55789 3/20 0.52
RAD52 P43351 2/20 0.52
HTT P42858 2/20 0.48
KDM4E B2RXH2 4/20 0.44
LMNA P02545 2/20 0.44
ALOX15 P16050 2/20 0.44
POLB P06746 2/20 0.38
MAPK1 P28482 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.36
PIK3CA P42336 1/20 0.36
ALDH1A3 P47895 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25183857 0.83 ALDH1A1 (0.55) MAPTALDH1A1GAAMEN1KMT2A
SCHEMBL13997364 0.83 SCN10A (0.46) MAPTALDH1A1GAAMEN1KMT2A
SCHEMBL30336193 0.83 ALDH1A1 (0.55) MAPTALDH1A1GAAMEN1KMT2A
SCHEMBL25207044 0.83 ALDH1A1 (0.65) MAPTALDH1A1GAAMEN1KMT2A
SCHEMBL31053515 0.83 ALDH1A1 (0.65) MAPTALDH1A1GAAMEN1KMT2A
SCHEMBL17264116 0.82 MAPT (0.69) MAPTALDH1A1GAAMEN1KMT2A
SCHEMBL31053586 0.82 ALDH1A1 (0.44) MAPTALDH1A1GAAMEN1KMT2A
SCHEMBL25190147 0.82 ALDH1A1 (0.44) MAPTALDH1A1GAAMEN1KMT2A
SCHEMBL14217240 0.81 ALDH1A1 (0.36) MAPTALDH1A1GAAMEN1KMT2A
SCHEMBL25190349 0.81 NR4A1 (0.47) MAPTALDH1A1GAAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240327393-A1 FERROPTOSIS MODULATORS, PREPARATIONS, AND USES THEREOF Sironax Ltd. (KY) 2024-10-03 US disclosed
CN-115151252-B Iron death inhibitor-diarylamine acetamides 维泰瑞隆有限公司 2024-08-27 CN disclosed
CN-117999259-A Iron death modulators, their preparation and use 维泰瑞隆有限公司 2024-05-07 CN disclosed
US-20230159492-A1 FERROPTOSIS INHIBITORS - DIARYLAMINE PARA-ACETAMIDES Sironax Ltd. (KY) 2023-05-25 US disclosed
WO-2023280296-A1 FERROPTOSIS MODULATORS, PREPARATIONS, AND USES THEREOF Sironax Ltd. (KY) 2023-01-12 WO disclosed
WO-2012053606-A1 ARYLAMINOHETEROCYCLIC CARBOXAMIDE COMPOUND アステラス製薬株式会社 (JP) 2012-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240327393-A1 FERROPTOSIS MODULATORS, PREPARATIONS, AND USES THEREOF AIFM2, GPX1, GPX4 MAPT 3110/4885ALDH1A1 1306/4885GAA 861/4885
US-20230159492-A1 FERROPTOSIS INHIBITORS - DIARYLAMINE PARA-ACETAMIDES AIFM2, FECH, GPX4 MAPT 4384/4885ALDH1A1 395/4885GAA 4193/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.